Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL738813 | 0.97 | FASN (0.48) | FASNSIGMAR1OPRM1MMP13LMNA | |
| SCHEMBL735789 | 0.97 | FASN (0.48) | FASNSIGMAR1OPRM1MMP13LMNA | |
| SCHEMBL737496 | 0.96 | FASN (0.47) | FASNSIGMAR1OPRM1MMP13LMNA | |
| SCHEMBL738666 | 0.85 | SIGMAR1 (0.59) | SIGMAR1OPRM1MMP13LMNAMAPT | |
| SCHEMBL737194 | 0.84 | SIGMAR1 (0.50) | SIGMAR1OPRM1MMP13LMNAMAPT | |
| SCHEMBL739140 | 0.84 | MAPT (0.45) | SIGMAR1OPRM1MMP13LMNAMAPT | |
| SCHEMBL737239 | 0.84 | SIGMAR1 (0.44) | SIGMAR1OPRM1MMP13LMNAMAPT | |
| SCHEMBL737024 | 0.83 | SIGMAR1 (0.43) | SIGMAR1OPRM1MMP13LMNAMAPT | |
| SCHEMBL739096 | 0.82 | SIGMAR1 (0.45) | SIGMAR1OPRM1MMP13LMNAMAPT | |
| SCHEMBL737590 | 0.82 | SIGMAR1 (0.55) | SIGMAR1OPRM1MMP13LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | FASN 4745/4885SIGMAR1 11/4885OPRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.